Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 4/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482735 | 0.77 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL489453 | 0.71 | — | — | |
| SCHEMBL77106 | 0.71 | CYP1A2 (1.00) | CYP1A2CYP2A6MAOAANPEPBCHE | |
| SCHEMBL29366435 | 0.71 | CYP1A2 (1.00) | CYP1A2CYP2A6MAOAANPEPBCHE | |
| SCHEMBL6479332 | 0.70 | CYP1A2 (0.48) | CYP1A2CYP2A6MAOAANPEP | |
| SCHEMBL6489138 | 0.69 | — | — | |
| SCHEMBL10463768 | 0.69 | CYP1A2 (0.94) | CYP1A2CYP2A6MAOAANPEPBCHE | |
| Ammonia Solution, Strong SCHEMBL13736473 | 0.69 | CYP1A2 (0.94) | CYP1A2CYP2A6MAOAANPEPBCHE | |
| SCHEMBL6480553 | 0.68 | CYP1A2 (0.45) | CYP1A2CYP2A6ANPEP | |
| SCHEMBL6480548 | 0.68 | CYP1A2 (0.45) | CYP1A2CYP2A6ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288238-A1 | Benzocyclodecane derivatives with antitumor activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OR10J3, BCL6 | CYP1A2 1712/4885CYP2A6 1673/4885MAOA 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.